Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Collaborator:
Ambit Biosciences Corporation
Information provided by (Responsible Party):
Daiichi Sankyo Inc.
ClinicalTrials.gov Identifier:
NCT01565668
First received: March 27, 2012
Last updated: November 11, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)